AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19
dc.contributor.author | Gupta, Shruti | |
dc.contributor.author | Coca, Steven G. | |
dc.contributor.author | Chan, Lili | |
dc.contributor.author | Melamed, Michal L. | |
dc.contributor.author | Brenner, Samantha K. | |
dc.contributor.author | Hayek, Salim S. | |
dc.contributor.author | Sutherland, Anne | |
dc.contributor.author | Puri, Sonika | |
dc.contributor.author | Srivastava, Anand | |
dc.contributor.author | Leonberg-Yoo, Amanda | |
dc.contributor.author | Shehata, Alexandre M. | |
dc.contributor.author | Flythe, Jennifer E. | |
dc.contributor.author | Rashidi, Arash | |
dc.contributor.author | Schenck, Edward J. | |
dc.contributor.author | Goyal, Nitender | |
dc.contributor.author | Hedayati, S. Susan | |
dc.contributor.author | Dy, Rajany | |
dc.contributor.author | Bansal, Anip | |
dc.contributor.author | Athavale, Ambarish | |
dc.contributor.author | Nguyen, H. Bryant | |
dc.contributor.author | Vijayan, Anitha | |
dc.contributor.author | Charytan, David M. | |
dc.contributor.author | Schulze, Carl E. | |
dc.contributor.author | Joo, Min J. | |
dc.contributor.author | Friedman, Allon N. | |
dc.contributor.author | Zhang, Jingjing | |
dc.contributor.author | Sosa, Marie Anne | |
dc.contributor.author | Judd, Eric | |
dc.contributor.author | Velez, Juan Carlos Q. | |
dc.contributor.author | Mallappallil, Mary | |
dc.contributor.author | Redfern, Roberta E. | |
dc.contributor.author | Bansal, Amar D. | |
dc.contributor.author | Neyra, Javier A. | |
dc.contributor.author | Liu, Kathleen D. | |
dc.contributor.author | Renaghan, Amanda D. | |
dc.contributor.author | Christov, Marta | |
dc.contributor.author | Molnar, Miklos Z. | |
dc.contributor.author | Sharma, Shreyak | |
dc.contributor.author | Kamal, Omer | |
dc.contributor.author | Boateng, Jeffery Owusu | |
dc.contributor.author | Short, Samuel A.P. | |
dc.contributor.author | Admon, Andrew J. | |
dc.contributor.author | Sise, Meghan E. | |
dc.contributor.author | Wang, Wei | |
dc.contributor.author | Parikh, Chirag R. | |
dc.contributor.author | Leaf, David E. | |
dc.contributor.author | STOP-COVID Investigators | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2023-05-01T15:12:44Z | |
dc.date.available | 2023-05-01T15:12:44Z | |
dc.date.issued | 2021 | |
dc.description.abstract | Background: AKI is a common sequela of coronavirus disease 2019 (COVID-19). However, few studies have focused on AKI treated with RRT (AKI-RRT). Methods: We conducted a multicenter cohort study of 3099 critically ill adults with COVID-19 admitted to intensive care units (ICUs) at 67 hospitals across the United States. We used multivariable logistic regression to identify patient-and hospital-level risk factors for AKI-RRT and to examine risk factors for 28-day mortality among such patients. Results: A total of 637 of 3099 patients (20.6%) developed AKI-RRT within 14 days of ICU admission, 350 of whom (54.9%) died within 28 days of ICU admission. Patient-level risk factors for AKI-RRT included CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dimer, and greater severity of hypoxemia on ICU admission. Predictors of 28-day mortality in patients with AKI-RRT were older age, severe oliguria, and admission to a hospital with fewer ICU beds or one with greater regional density of COVID-19. At the end of a median follow-up of 17 days (range, 1-123 days), 403 of the 637 patients (63.3%) with AKI-RRT had died, 216 (33.9%) were discharged, and 18 (2.8%) remained hospitalized. Of the 216 patients discharged, 73 (33.8%) remained RRT dependent at discharge, and 39 (18.1%) remained RRT dependent 60 days after ICU admission. Conclusions: AKI-RRT is common among critically ill patients with COVID-19 and is associated with a hospital mortality rate of >60%. Among those who survive to discharge, one in three still depends on RRT at discharge, and one in six remains RRT dependent 60 days after ICU admission. | en_US |
dc.identifier.citation | Gupta S, Coca SG, Chan L, et al. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161-176. doi:10.1681/ASN.2020060897 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/32732 | |
dc.language.iso | en_US | en_US |
dc.publisher | Wolters Kluwer | en_US |
dc.relation.isversionof | 10.1681/ASN.2020060897 | en_US |
dc.relation.journal | Journal of the American Society of Nephrology | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Acute kidney injury | en_US |
dc.subject | Acute renal failure | en_US |
dc.subject | Clinical epidemiology | en_US |
dc.subject | Dialysis | en_US |
dc.subject | Renal replacement therapy | en_US |
dc.subject | Risk factors | en_US |
dc.title | AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19 | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894677/ | en_US |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.pdf
- Size:
- 6.57 MB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: